image credit: Unsplash

FDA advisers meet to review J&J’s one-shot coronavirus vaccine

February 26, 2021

A group of advisers to the Food and Drug Administration is meeting Friday to discuss whether the agency should clear Johnson & Johnson’s coronavirus vaccine for emergency use.

Results from a large international study of roughly 40,000 volunteers found the shot was 66% effective in preventing moderate or severe COVID-19, although protection appeared weaker against a virus variant first detected in South Africa. FDA scientists reviewing the vaccine affirmed J&J’s findings in documents published Wednesday.

Read More on Biopharma Dive